ANI Grabs 23 US Products From Amerigen
Deal Boosts Both Portfolio And Pipeline
In a deal worth up to $77.5m, ANI has acquired rights to 12 marketed generics in the US, as well as to another 11 pipeline products, from Amerigen.
You may also be interested in...
ANI revealed last month that long-serving company head Arthur Przybyl would be departing after 11 years at the top. The US-based player has just announced its interim chief as it reported first-quarter sales, following the landmark US portfolio acquisition from Amerigen in January, and made a major announcement for its full-year financial guidance.
ANI Pharmaceuticals has been steered by former Akorn head Arthur Przybyl since March 2009. But he will bring the curtain down on his time with the company next month, as the company recruits his replacement ahead of a key branded product launch.
Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.